Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.54 |
| ▸ | PTGES | O14684 | 3/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 3/20 | 0.53 |
| ▸ | CES1 | P23141 | 3/20 | 0.53 |
| ▸ | APEX1 | P27695 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28271475 | 1.00 | LMNA (0.66) | LMNATDP1ALOX5PTGESPPARG | |
| SCHEMBL17629136 | 1.00 | LMNA (0.66) | LMNATDP1ALOX5PTGESPPARG | |
| SCHEMBL5467260 | 0.98 | TDP1 (0.67) | LMNATDP1ALOX5PTGESPPARG | |
| SCHEMBL9302259 | 0.98 | TDP1 (0.67) | LMNATDP1ALOX5PTGESPPARG | |
| SCHEMBL3250732 | 0.98 | TDP1 (0.67) | LMNATDP1ALOX5PTGESPPARG | |
| SCHEMBL6437828 | 0.98 | TDP1 (0.67) | LMNATDP1ALOX5PTGESPPARG | |
| SCHEMBL3684325 | 0.98 | TDP1 (0.67) | LMNATDP1ALOX5PTGESPPARG | |
| SCHEMBL489897 | 0.98 | TDP1 (0.67) | LMNATDP1ALOX5PTGESPPARG | |
| SCHEMBL5467262 | 0.98 | TDP1 (0.67) | LMNATDP1ALOX5PTGESPPARG | |
| SCHEMBL27679125 | 0.98 | TDP1 (0.67) | LMNATDP1ALOX5PTGESPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160089317-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | claimed |
| US-20160090555-A1 | CLEANING AND/OR TREATMENT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | claimed |
| US-11326014-B2 | Vinyl aromatic/diene-block copolymers having good organoleptic properties | INEOS STYROLUTION GROUP GMBH (DE) | 2022-05-10 | — | — | US | disclosed |
| US-20200207901-A1 | VINYL AROMATIC/DIENE-BLOCK COPOLYMERS HAVING GOOD ORGANOLEPTIC PROPERTIES | HSBC CORPORATE TRUSTEE COMPANY (UK) LIMITED (GB) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160089317-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | LPO, QDPR, TYR | LMNA 4565/4885TDP1 2670/4885ALOX5 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.